A more recent addition to my transformational technologies portfolio, Medarex (NASDAQ:MEDX), has scored a huge win. The company, along with Massachusetts Biologic Laboratory, will get $60 million upfront from Merck (NYSE:MRK) for license rights to a monoclonal antibody that apparently cures C. difficile infection. They are eligible for another $165 million in milestones as well as royalties.

Last May, shares of Regeneron Pharmaceuticals (REGN), a billion-dollar biotech, slid 35% in just 30 days. The company had no press releases, no earnings reports, nothing.